These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 29898788)

  • 1. Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors.
    Hammond E; Haynes NM; Cullinane C; Brennan TV; Bampton D; Handley P; Karoli T; Lanksheer F; Lin L; Yang Y; Dredge K
    J Immunother Cancer; 2018 Jun; 6(1):54. PubMed ID: 29898788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives.
    Hammond E; Dredge K
    Adv Exp Med Biol; 2020; 1221():539-565. PubMed ID: 32274726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
    Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
    Dredge K; Brennan TV; Hammond E; Lickliter JD; Lin L; Bampton D; Handley P; Lankesheer F; Morrish G; Yang Y; Brown MP; Millward M
    Br J Cancer; 2018 Apr; 118(8):1035-1041. PubMed ID: 29531325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(1):109-121. PubMed ID: 30142009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory Activities of the Heparan Sulfate Mimetic PG545.
    Bendersky V; Yang Y; Brennan TV
    Adv Exp Med Biol; 2020; 1221():461-470. PubMed ID: 32274722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
    O'Neill C; Hayat T; Hamm J; Healey M; Zheng Q; Li Y; Martin RCG
    Surgery; 2020 Oct; 168(4):610-616. PubMed ID: 32631655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
    Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
    Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1
    Wang J; Cheng X; Jin Y; Xia B; Qin R; Zhang W; Hu H; Mao X; Zhou L; Yan J; Zhang X; Xu J
    Cancer Res Commun; 2023 Jun; 3(6):991-1003. PubMed ID: 37377605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
    Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
    J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer.
    Ding G; Shen T; Yan C; Zhang M; Wu Z; Cao L
    BMC Cancer; 2019 Nov; 19(1):1053. PubMed ID: 31694582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab: A Review in Advanced Melanoma.
    Scott LJ
    Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway.
    Pu N; Gao S; Yin H; Li JA; Wu W; Fang Y; Zhang L; Rong Y; Xu X; Wang D; Kuang T; Jin D; Yu J; Lou W
    Cancer Lett; 2019 Sep; 460():42-53. PubMed ID: 31233838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
    Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
    Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
    Kokowski K; Stangl S; Seier S; Hildebrandt M; Vaupel P; Multhoff G
    Strahlenther Onkol; 2019 Apr; 195(4):352-361. PubMed ID: 30747241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.